What does Dr. Galdermans Daniella, pneumoloog - oncoloog do?

Dr. Galdermans Daniella, pneumoloog - oncoloog is a general practice in Aartselaar. Private Limited, started on 20 July 2021, 1 establishment.

What is the address of Dr. Galdermans Daniella, pneumoloog - oncoloog?

The registered office of Dr. Galdermans Daniella, pneumoloog - oncoloog is located at Kontichsesteenweg 94, 2630 Aartselaar.

Is Dr. Galdermans Daniella, pneumoloog - oncoloog still active?

Yes. According to the CBE (18 September 2026) Dr. Galdermans Daniella, pneumoloog - oncoloog is active, legal situation “Normale toestand”, started on 20 July 2021.

Is Dr. Galdermans Daniella, pneumoloog - oncoloog registered on Peppol?

No, Dr. Galdermans Daniella, pneumoloog - oncoloog is currently not registered on the Peppol network.

What is the enterprise number of Dr. Galdermans Daniella, pneumoloog - oncoloog?

The enterprise number of Dr. Galdermans Daniella, pneumoloog - oncoloog is BE0771604019.

When was Dr. Galdermans Daniella, pneumoloog - oncoloog founded?

Dr. Galdermans Daniella, pneumoloog - oncoloog was founded on 20 July 2021.

Who are the directors of Dr. Galdermans Daniella, pneumoloog - oncoloog?

According to the 2025 annual accounts, the directors of Dr. Galdermans Daniella, pneumoloog - oncoloog are: Daniella Galdermans.

Is Dr. Galdermans Daniella, pneumoloog - oncoloog a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 20 July 2021; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Dr. Galdermans Daniella, pneumoloog - oncoloog make in 2025?

Dr. Galdermans Daniella, pneumoloog - oncoloog posted a profit after taxes of € 28,289 in financial year 2025.

What is the revenue of Dr. Galdermans Daniella, pneumoloog - oncoloog?

As a small company, Dr. Galdermans Daniella, pneumoloog - oncoloog is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -3,581.

Dr. Galdermans Daniella, pneumoloog - oncoloog (Private Limited)

Dossier Dr. Galdermans Daniella, pneumoloog - oncoloog, printed on 18 September 2026 from databakkes.be/en/0771604019/dr-galdermans-daniella-pneumoloog-oncoloog. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

Dr. Galdermans Daniella, pneumoloog - oncoloog from Aartselaar, company number BE0771604019, closed financial year 2025 with a result of € 28,289 after tax. For that financial year Dr. Galdermans Daniella, pneumoloog - oncoloog recorded a gross margin of € -3,581 and equity of € 432,416. Compared with financial year 2024, the result moved from € 118,713 to € 28,289. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 29, 2026.

What it is worth Growing

€ 432,416

▲ 7% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 28,289

▼ 76% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 20,284

▼ 29% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 833 paid out

3 % of the profit went to the shareholders, the rest stayed in the company.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 396

▼ 82% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 18,430

▲ 41% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 214,776 Gross margin 2022: € 214,776 First fiscal year in the series	€ 196,555 Gross margin 2023: € 196,555 ▼ 8% vs 2022 (€ 214,776) Unfavourable step	€ 178,755 Gross margin 2024: € 178,755 ▼ 9% vs 2023 (€ 196,555) Unfavourable step	€ -3,581 Gross margin 2025: € -3,581 ▼ € 182,336 vs 2024 (€ 178,755) Unfavourable step	▼ € 182,336
Profit after taxes	€ 155,461 Profit after taxes 2022: € 155,461 First fiscal year in the series	€ 131,278 Profit after taxes 2023: € 131,278 ▼ 16% vs 2022 (€ 155,461) Unfavourable step	€ 118,713 Profit after taxes 2024: € 118,713 ▼ 10% vs 2023 (€ 131,278) Unfavourable step	€ 28,289 Profit after taxes 2025: € 28,289 ▼ 76% vs 2024 (€ 118,713) Unfavourable step	▼ 76%
Equity	€ 156,661 Equity 2022: € 156,661 First fiscal year in the series	€ 287,106 Equity 2023: € 287,106 ▲ 83% vs 2022 (€ 156,661) Favourable step	€ 404,960 Equity 2024: € 404,960 ▲ 41% vs 2023 (€ 287,106) Favourable step	€ 432,416 Equity 2025: € 432,416 ▲ 7% vs 2024 (€ 404,960) Favourable step	▲ 7%
Total debts	€ 19,293 Total debts 2022: € 19,293 First fiscal year in the series	€ 31,913 Total debts 2023: € 31,913 ▲ 65% vs 2022 (€ 19,293) Unfavourable step	€ 21,484 Total debts 2024: € 21,484 ▼ 33% vs 2023 (€ 31,913) Favourable step	€ 23,934 Total debts 2025: € 23,934 ▲ 11% vs 2024 (€ 21,484) Unfavourable step	▲ 11%
Cash	€ 90,307 Cash 2022: € 90,307 First fiscal year in the series	€ 8,089 Cash 2023: € 8,089 ▼ 91% vs 2022 (€ 90,307) Unfavourable step	€ 28,701 Cash 2024: € 28,701 ▲ 255% vs 2023 (€ 8,089) Favourable step	€ 20,284 Cash 2025: € 20,284 ▼ 29% vs 2024 (€ 28,701) Unfavourable step	▼ 29%
Retained profit	€ 154,661 Retained profit 2022: € 154,661 First fiscal year in the series	€ 285,106 Retained profit 2023: € 285,106 ▲ 84% vs 2022 (€ 154,661) Favourable step	€ 402,960 Retained profit 2024: € 402,960 ▲ 41% vs 2023 (€ 285,106) Favourable step	€ 430,416 Retained profit 2025: € 430,416 ▲ 7% vs 2024 (€ 402,960) Favourable step	▲ 7%
Dividend	€ 800 Dividend 2022: € 800 First fiscal year in the series	€ 833 Dividend 2023: € 833 ▲ 4% vs 2022 (€ 800) Unchanged	€ 859 Dividend 2024: € 859 ▲ 3% vs 2023 (€ 833) Unchanged	€ 833 Dividend 2025: € 833 ▼ 3% vs 2024 (€ 859) Unchanged	▼ 3%
Balance sheet total	€ 175,955 Balance sheet total 2022: € 175,955 First fiscal year in the series	€ 319,019 Balance sheet total 2023: € 319,019 ▲ 81% vs 2022 (€ 175,955) Unchanged	€ 426,444 Balance sheet total 2024: € 426,444 ▲ 34% vs 2023 (€ 319,019) Unchanged	€ 456,350 Balance sheet total 2025: € 456,350 ▲ 7% vs 2024 (€ 426,444) Unchanged	▲ 7%

Key figures of Dr. Galdermans Daniella, pneumoloog - oncoloog, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Dr. Galdermans Daniella, pneumoloog - oncoloog?

What happened at Dr. Galdermans Daniella, pneumoloog - oncoloog in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 29, 2026 New annual accounts for financial year 2025: profit of € 28,289 (▼ 76% vs 2024). Source: NBB ↗
Jul 20, 2021 New establishment in Aartselaar. KBO
Jul 20, 2021 Start of the company according to the CBE. KBO

In short

From € 155,461 profit in 2022 to € 28,289 profit in 2025.

Paid € 184,848 in corporate taxes since 2022.

Best year ever: 2022, with € 155,461 profit.

Paid out € 3,325 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at Dr. Galdermans Daniella, pneumoloog - oncoloog? We notify you, reason included.

Follow Dr. Galdermans Daniella, pneumoloog - oncoloog

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Daniella Galdermans

Dr. Galdermans Daniella, pneumoloog - oncoloog

Behind Dr. Galdermans Daniella, pneumoloog - oncoloog is Daniella Galdermans.

See the full network in the app

Directors

According to the 2025 annual accounts

Daniella Galdermans

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Kontichsesteenweg 94

2630 Aartselaar

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0771.604.019
VAT number: BE 0771.604.019
Registered office: Kontichsesteenweg 94, 2630 Aartselaar
Names & denominations: Dr. Galdermans Daniella, pneumoloog - oncoloog
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 20 July 2021
Peppol: Not registered
Activities · NACE: Activiteiten van huisartspraktijken

View on CBE Public ↗ Annual accounts (NBB) ↗